Edwards Lifesciences [EW] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Edwards Lifesciences Corporation

NYSE
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Edwards Lifesciences Corporation wins in 7 metrics, Abbott Laboratories wins in 12 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Edwards Lifesciences Corporation Abbott Laboratories Better
P/E Ratio (TTM) 46.49 25.97 Abbott Laboratories
Price-to-Book Ratio 4.73 3.09 Abbott Laboratories
Debt-to-Equity Ratio 6.82 26.79 Edwards Lifesciences Corporation
PEG Ratio -0.62 -1.41 Edwards Lifesciences Corporation
EV/EBITDA 23.85 13.74 Abbott Laboratories
Profit Margin (TTM) 17.39% 13.90% Edwards Lifesciences Corporation
Operating Margin (TTM) 31.22% 16.50% Edwards Lifesciences Corporation
EBITDA Margin (TTM) 31.22% 16.50% Edwards Lifesciences Corporation
Return on Equity 10.38% 12.36% Abbott Laboratories
Return on Assets (TTM) 7.84% 7.52% Edwards Lifesciences Corporation
Free Cash Flow (TTM) $1.34B $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return 13.25% -34.98% Edwards Lifesciences Corporation
Price-to-Sales Ratio (TTM) 7.70 3.57 Abbott Laboratories
Enterprise Value $45.35B $166.96B Abbott Laboratories
EV/Revenue Ratio 7.20 3.70 Abbott Laboratories
Gross Profit Margin (TTM) 78.15% N/A N/A
Revenue per Share (TTM) $11 $26 Abbott Laboratories
Earnings per Share (Diluted) $1.81 $3.57 Abbott Laboratories
Beta (Stock Volatility) 0.95 0.78 Abbott Laboratories
Short % of Float 1.84% 1.53% Abbott Laboratories

Edwards Lifesciences Corporation vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

EW
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Edwards Lifesciences Corporation1.37%0.50%6.02%3.26%3.48%1.11%
Abbott Laboratories0.56%-2.02%4.97%-19.35%-30.98%-28.60%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Edwards Lifesciences Corporation13.25%-7.43%-15.49%159.09%507.93%2,151.59%
Abbott Laboratories-34.98%-16.97%-20.08%135.84%255.56%329.52%

Performance & Financial Health Analysis: Edwards Lifesciences Corporation vs Abbott Laboratories

MetricEWABT
Market Information
Market Cap i$48.52B$160.70B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i6,242,65013,495,583
90 Day Avg. Volume i5,032,27012,934,461
Last Close$86.28$88.67
52 Week Range$72.30 - $89.48$81.97 - $139.06
% from 52W High-3.58%-36.24%
All-Time High$131.73 (Dec 27, 2021)$142.60 (Dec 27, 2021)
% from All-Time High-34.50%-37.82%
Growth Metrics
Quarterly Revenue Growth0.17%0.08%
Quarterly Earnings Growth0.06%-0.19%
Financial Health
Profit Margin (TTM) i0.17%0.14%
Operating Margin (TTM) i0.31%0.17%
Return on Equity (TTM) i0.10%0.12%
Debt to Equity (MRQ) i6.8226.79
Cash & Liquidity
Book Value per Share (MRQ)$17.80$30.02
Cash per Share (MRQ)$7.28$5.14
Operating Cash Flow (TTM) i$1.50B$10.80B
Levered Free Cash Flow (TTM) i$1.07B$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: Edwards Lifesciences Corporation vs Abbott Laboratories

MetricEW (Apr 26, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i46.4925.97
Forward P/E i25.0515.29
PEG Ratio i-0.62-1.41
Price to Sales (TTM) i7.703.57
Price to Book (MRQ) i4.733.09
Market Capitalization
Market Capitalization i$48.52B$160.70B
Enterprise Value i$45.35B$166.96B
Enterprise Value Metrics
Enterprise to Revenue i7.203.70
Enterprise to EBITDA i23.8513.74
Risk & Other Metrics
Beta i0.950.78
Book Value per Share (MRQ) i$17.80$30.02

Financial Statements Comparison: Edwards Lifesciences Corporation vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricEW (2025)ABT (2025)
Revenue/Sales i6.07B44.33B
Cost of Goods Sold i1.33B19.32B
COGS % of Revenue i22.0%43.6%
Gross Profit i4.73B25.01B
Gross Margin i78.0%56.4%
Research & Development i1.08B2.94B
Operating Income (EBIT) i1.64B8.05B
Operating Margin i27.0%18.2%
EBITDA i1.96B12.03B
EBITDA Margin i32.4%27.1%
Pre-Tax Income i1.27B8.47B
Pre-Tax Income % of Revenue i21.0%19.1%
Income Tax i216.90M1.94B
Income Tax % of Revenue i3.6%4.4%
Net Income (Profit) i1.07B6.52B
Profit Margin i17.6%14.7%

Balance Sheet & Liquidity Metrics

MetricEW (2025)ABT (2025)
Cash & Equivalents i2.94B8.52B
Total Current Assets i6.74B26.00B
Total Current Assets % of Revenue i111.1%58.6%
Total Current Liabilities i1.81B16.50B
Total Current Liabilities % of Revenue i29.9%37.2%
Long-Term Debt i680.90M10.83B
Long-Term Debt % of Revenue i11.2%24.4%
Total Shareholders Equity i10.34B52.77B
Retained Earnings i14.24B49.78B
Retained Earnings % of Revenue i234.7%112.3%
Property, Plant & Equipment i102.70M17.57B

Cash Flow Statement Comparison

MetricEW (2025)ABT (2025)
Operating Cash Flow i1.50B10.80B
Operating Cash Flow % of Revenue i24.7%24.4%
Capital Expenditures iN/A-2.17B
Free Cash Flow i1.34B7.40B
FCF Margin i22.0%16.7%
Debt Repayment iN/A-1.50B
Common Stock Repurchase i-893.40M-893.00M

Short Interest & Institutional Ownership Analysis

MetricEWABT
Shares Short i9.33M23.83M
Short Ratio i2.051.93
Short % of Float i1.84%1.53%
Shares Outstanding i580.70M1.74B
Float Shares i579.02M1.73B
% Held by Insiders i0.17%0.54%
% Held by Institutions i92.88%82.23%
% Held by Public i6.95%17.23%

Dividend Analysis & Yield Comparison: Edwards Lifesciences Corporation vs Abbott Laboratories

MetricEWABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026